Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.

The Danish pharmaceutical company expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.